Age: 18 to75 years old;
Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1);
Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;
ECOG PS of 0-2;
HB = 90g / L
ANC = 1.5 × 109 / L
PLT = 80 × 109 / L
Bilirubin <1.25 times the upper limit of normal (ULN)
ALT and AST <2.5 × ULN; liver metastases, if any, the ALT and AST<5 × ULN
Serum Cr = 1 × ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula)
An expected survival of = 3 months;
Patient received apatinib treatment regimen at investigators' discretion;
Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.

NCT02426034_inc_T1
Person
Age
NCT02426034_inc_T2
Value
18 to75 years old
NCT02426034_inc_T3
Condition
advanced gastric cancer
NCT02426034_inc_T4
Condition
adenocarcinoma
NCT02426034_inc_T5
Qualifier
gastroesophageal junction
NCT02426034_inc_T6
Condition
metastases
NCT02426034_inc_T7
Negation
outside
NCT02426034_inc_T8
Qualifier
stomach
NCT02426034_inc_T9
Multiplier
at least two
NCT02426034_inc_T10
Procedure
chemotherapy
NCT02426034_inc_T11
Qualifier
Failure
NCT02426034_inc_T12
Measurement
ECOG PS
NCT02426034_inc_T13
Value
0-2
NCT02426034_inc_T14
Measurement
HB
NCT02426034_inc_T15
Value
= 90g / L
NCT02426034_inc_T16
Measurement
ANC
NCT02426034_inc_T17
Value
= 1.5 × 109 / L
NCT02426034_inc_T18
Measurement
PLT
NCT02426034_inc_T19
Value
= 80 × 109 / L
NCT02426034_inc_T20
Measurement
Bilirubin
NCT02426034_inc_T21
Value
<1.25 times the upper limit of normal
NCT02426034_inc_T22
Measurement
ALT
NCT02426034_inc_T23
Measurement
AST
NCT02426034_inc_T24
Value
<2.5 × ULN
NCT02426034_inc_T25
Condition
liver metastases
NCT02426034_inc_T26
Measurement
ALT
NCT02426034_inc_T27
Measurement
AST
NCT02426034_inc_T28
Value
<5 × ULN
NCT02426034_inc_T29
Scope
ALT and AST
NCT02426034_inc_T30
Measurement
Serum Cr
NCT02426034_inc_T31
Value
= 1 × ULN
NCT02426034_inc_T32
Measurement
endogenous creatinine clearance
NCT02426034_inc_T33
Value
>50ml/min
NCT02426034_inc_T34
Observation
expected survival
NCT02426034_inc_T35
Value
= 3 months
NCT02426034_inc_T36
Drug
apatinib